Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi

References

• Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105(11):1684–1692.
   PubMed Web of Science ®Google Scholar
• Kumar A, Sha F, Toure A, et al. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood Cancer J. 2019;9(6):50.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105(7):2677–2684.
   PubMed Web of Science ®Google Scholar
• Hermine O, Hoster E, Walewski J, et al. Alternating courses of 3 X CHOP and 3 X DHAP plus Rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation increases overall survival when compared to 6 courses of CHOP plus Rituximab followed by myeloablative radiochemotherapy and ASCT in MCL Network. Blood. 2012;120(21):151–151.
   Web of Science ®Google Scholar
• Romaguera JE, Fayad LE, Feng L, et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol. 2010;150(2):200–208.
   PubMed Web of Science ®Google Scholar
• Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem cell transplantation in mantle cell lymphoma. N Engl J Med. 2017;377(13):1250–1260.
   PubMed Web of Science ®Google Scholar
• Dietrich S, Boumendil A, Finel H, et al. Outcome and prognostic factors in patients with mantle cell lymphoma relapsing after autologous stem cell transplantation. Ann Oncol. 2014;25(5):1053–1058.
   PubMed Web of Science ®Google Scholar
• Visco C, Tisi MC, Evangelista A, Fondazione Italiana Linfomi and the Mantle Cell Lymphoma Network, et al. Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. Br J Haematol. 2019;185(5):940–944.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Campo E, Hermine O, ESMO Guidelines Committee, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl_4):iv62–iv71.
   PubMedGoogle Scholar
• Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–516.
   PubMed Web of Science ®Google Scholar
• Wang M, Rule S, Zinzani PL, et al. Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia. 2019;33(11):2762–2766.
   PubMed Web of Science ®Google Scholar
• Song Y, Zhou K, Zou D, et al. Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton's Tyrosine Kinase. Clin Cancer Res. 2020;26(16):4216–4224.
   PubMed Web of Science ®Google Scholar
• Eskelund CW, Dahl C, Hansen JW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130(17):1903–1910.
   PubMed Web of Science ®Google Scholar
• Lin RJ, Ho C, Hilden P, et al. Allogenic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations. B J Haematol. 2019;184:1006–1010.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Klapper W, Rule S. Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge. Blood. 2018;132(26):2722–2729.
   PubMed Web of Science ®Google Scholar
• Hoster E, Rosenwald A, Berger F, et al. Prognostic value of Ki-67 Index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network. J Clin Oncol. 2016;34(12):1386–1394.
   PubMed Web of Science ®Google Scholar
• Robinson SP, Boumendil A, Finel H, et al. Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party. Bone Marrow Transplant. 2018;53(5):617–624.
   PubMed Web of Science ®Google Scholar
• Vaughn J, Sorror ML, Storer BE, et al. Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Cancer. 2015;121(20):3709–3716.
   PubMed Web of Science ®Google Scholar
• Gayoso J, Martino R, Balsalobre P, et al. Long-term results of fludarabine/melphalan as a reduced-intensity conditioning regimen in mantle cell lymphoma: the GELTAMO experience. Ther Adv Hematol. 2011;2(1):5–10.
   PubMedGoogle Scholar
• Tam C, Bassett R, Ledesma C, et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood. 2009;113(18):4144–4152.
   PubMed Web of Science ®Google Scholar
• Cook G, Smith GM, Kirkland K, et al. Outcome following reduced intensity allogenic stem cell transplantation for relapsed and refractory MCL: a study of the British society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2010;16(10):1419–1427.
   PubMed Web of Science ®Google Scholar
• Le Gouill S, Kroger N, Dhedin N, et al. Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. Ann Oncol. 2012;23(10):2695–2703.
   PubMed Web of Science ®Google Scholar
• Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab containing reduced intensity allogenic transplantation regimen for relapsed and refractory non hodgkin lymphoma. Blood. 2004;104(13):3865–3871.
   PubMed Web of Science ®Google Scholar
• Hamadani M, Saber W, Ahn KW, et al. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research . Biol Blood Marrow Transplant. 2013;19(4):625–631.
   PubMed Web of Science ®Google Scholar
• Tessoulin B, Ceballos P, Chevallier P, et al. Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC. Bone Marrow Transplant. 2016;51(9):1184–1190.
   PubMed Web of Science ®Google Scholar
• Mussetti A, Devlin SM, Castro-Malaspina HR, et al. Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era. Bone Marrow Transplant. 2015;50(10):1293–1298.
   PubMed Web of Science ®Google Scholar
• Dreger P, Michallet M, Bosman P, et al. Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. Bone Marrow Transplant. 2019;54(1):44–52.
   PubMed Web of Science ®Google Scholar
• Visco C, Di Rocco A, Evangelista A, et al. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. Leukemia. 2021;35(3):787–795.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–2919.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628–1633.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825–828.
   PubMed Web of Science ®Google Scholar
• Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945–956.
   PubMed Web of Science ®Google Scholar
• Corradini P, Dodero A, Farina L, on behalf of Gruppo Italiano Trapianto di Midollo Osseo (GITMO), et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia. 2007;21(11):2316–2323.
   PubMed Web of Science ®Google Scholar
• Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–650.
   PubMed Web of Science ®Google Scholar
• Shah NN, Hamadani M. Is there still a role for allogeneic transplantation in the management of lymphoma? J Clin Oncol. 2021;39(5):487–498.
   PubMed Web of Science ®Google Scholar
• Marangon M, Visco C, Barbui AM, et al. Allogeneic stem cell transplantation in mantle cell lymphoma in the era of new drugs and CAR-T cell therapy. Cancers (Basel). 2021;13(2):291.
   PubMed Web of Science ®Google Scholar
• Martin P, Maddocks K, Leonard JP, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127(12):1559–1563.
   PubMed Web of Science ®Google Scholar
• Jain P, Kanagal-Shamanna R, Zhang S, et al. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol. 2018;183(4):578–587.
   PubMed Web of Science ®Google Scholar
• Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331–1342.
   PubMed Web of Science ®Google Scholar
• Palomba ML, Gordon LI, Siddiqi T, et al. Safety and preliminary efficacy in patients with relapsed/refractory mantle cell lymphoma receiving Lisocabtagene Maraleucel in Transcend NHL 001. 62nd ASH annual meeting and exposition. Abs 118.
   Google Scholar